1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 130,00 | 133,00 | 17.07. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BELITE BIO Aktie jetzt für 0€ handeln | |||||
| 09.07. | Belite Bio: Phase-3-Daten stützen Zulassungsantrag für Tinlarebant | 4 | Investing.com Deutsch | ||
| 16.06. | Belite Bio: H.C. Wainwright bestätigt Kursziel von 200 Dollar nach Abschluss des Zulassungsantrags | 1 | Investing.com Deutsch | ||
| 16.06. | Belite Bio stock price target maintained at $200 by H.C. Wainwright on NDA completion | 3 | Investing.com | ||
| 13.06. | BELITE BIO, INC - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 13.06. | Belite Bio, Inc: Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 | 542 | GlobeNewswire (Europe) | SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) ("Belite Bio" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting... ► Artikel lesen | |
| 01.06. | Full Transcript: Belite Bio Q1 2026 Earnings Call | 2 | Benzinga.com | ||
| 26.05. | Mizuho lowers Belite Bio stock price target to $215 on valuation | 2 | Investing.com | ||
| 22.05. | Benchmark reiterates Belite Bio stock rating on drug development progress | 5 | Investing.com | ||
| 21.05. | H.C. Wainwright reiterates Belite Bio stock rating on NDA progress | 2 | Investing.com | ||
| 21.05. | Belite Bio targets completing stargardt NDA rolling submission in Q2 2026 while planning a 30-40 member U.S. launch team | 2 | Seeking Alpha | ||
| 20.05. | Belite Bio übertrifft EPS-Prognose für Q1 2026, Aktie gibt dennoch nach | 3 | Investing.com Deutsch | ||
| 20.05. | Belite Bio Non-GAAP EPS of -$0.34 beats by $0.30 | 3 | Seeking Alpha | ||
| 20.05. | Belite Bio übertrifft Erwartungen im ersten Quartal - Aktie legt zu | 3 | Investing.com Deutsch | ||
| 20.05. | Belite Bio, Inc: Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update | 455 | GlobeNewswire (Europe) | Initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant for the treatment of Stargardt disease type 1 (STGD1); submission expected... ► Artikel lesen | |
| 20.05. | BELITE BIO, INC - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 18.05. | Belite Bio receives Swiss orphan drug status for tinlarebant | 3 | Investing.com | ||
| 18.05. | Belite Bio, Inc: Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland | 296 | GlobeNewswire (Europe) | Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease, having met the primary endpoint, reductions in lesion growth rate, in the pivotal, global Phase... ► Artikel lesen | |
| 13.05. | Belite Bio, Inc: Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results | 4 | GlobeNewswire (USA) | ||
| 21.04. | Belite Bio begins rolling NDA submission for Stargardt treatment | 2 | Investing.com | ||
| 21.04. | Belite Bio startet schrittweises Zulassungsverfahren für Stargardt-Therapie | 1 | Investing.com Deutsch |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 41,765 | -1,66 % | 3 Reasons to Buy CRISPR Therapeutics Stock | ||
| PALATIN TECHNOLOGIES | 9,000 | +6,19 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Announces Asset Sale Agreements; Commences Chapter 11 Proceedings | INDIANAPOLIS (dpa-AFX) - Sangamo Therapeutics has entered into two separate asset sale agreements, one with Eli Lilly and Company (LLY) for Sangamos capsid delivery platform, zinc finger platform... ► Artikel lesen | |
| ABIVAX | 120,90 | +0,83 % | Abivax-Aktie: Analysten erhöhen Prognosen - diese Woche Übernahmeknall? | Die Abivax-Aktie bleibt einer der spannendsten Biotech-Werte des Jahres. Nachdem Reuters zuletzt bestätigt hatte, dass der französische Wirkstoffentwickler mit mehreren Interessenten über eine mögliche... ► Artikel lesen | |
| GERON | 1,240 | -0,44 % | Geron Corporation: Geron Announces Appointment of Chinmaya Rath as Chief Business Officer | FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,540 | -1,55 % | Cellectar publishes phase 1 data on multiple myeloma treatment | ||
| ARGENX | 753,00 | +0,45 % | argenx SE: argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026 | ||
| MUSTGROW BIOLOGICS | 0,210 | +0,96 % | Die Zukunft der Ernährung: Große Chancen für MustGrow und K+S! Wie geht es nach dem Absturz bei Evotec weiter? | Erstellt und veröffentlicht im Auftrag von MustGrow Biologics Corp. Die globale Lebensmittelversorgung steht vor einem tiefgreifenden Wandel. Eine wachsende Weltbevölkerung, die Erderwärmung und strengere... ► Artikel lesen | |
| CYTOKINETICS | 68,32 | -2,76 % | Wall Street Analysts Think Cytokinetics (CYTK) Could Surge 30.54%: Read This Before Placing a Bet | ||
| BEAM THERAPEUTICS | 27,530 | 0,00 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,240 | +1,12 % | CytomX Therapeutics Inc.: CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer | - Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX's PROBODY- and Regeneron's Veloci-Bi- platforms - - CytomX to receive... ► Artikel lesen | |
| ZAI LAB LTD ADR | 17,100 | -6,04 % | Zai Lab Limited: Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas | Zoci, a potential first-in-class DLL3-targeting antibody drug conjugate, showed a 53.7% confirmed intracranial objective response rate (iORR) for small cell lung cancer (SCLC) with brain metastases... ► Artikel lesen | |
| CYBIN | 6,310 | +2,60 % | CYBIN INC. - 6-K, Report of foreign issuer | ||
| XBIOTECH | 1,958 | -2,10 % | XBiotech Inc.: XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis | IND Application for V-SPINE Study Completes 30-Day FDA Review Without Clinical Hold, Clearing Path for U.S. Patient Enrollment
AUSTIN, Texas, June 15, 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:... ► Artikel lesen | |
| KYNTRA BIO | 6,200 | -5,34 % | Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update | Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is progressing well with the... ► Artikel lesen |
Das Unternehmen BELITE BIO INC ADR kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -1,00 (-0,76 %) liegt der Kurs bei 130,00 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BELITE BIO INC ADR finden Sie auf Wallstreet Online.